In a female nursing professional with a long‑standing history of generalized anxiety disorder who recently had a manic episode with psychotic features requiring inpatient treatment and is now experiencing residual anxiety, depressive symptoms, and sedation from olanzapine, what are the most likely primary diagnosis and the key differential diagnoses?

Primary Diagnosis: Bipolar I Disorder, Current Episode Depressed, with Anxious Distress

The most likely primary diagnosis is Bipolar I Disorder, current episode depressed with anxious distress, given the well-documented manic episode with psychotic features in August 2024 requiring multiple hospitalizations, followed by current residual depressive and anxiety symptoms. The diagnosis of Bipolar I requires only one lifetime manic episode, which this patient clearly experienced with grandiose delusions, paranoia, tactile hallucinations, severe insomnia, and marked functional impairment 1, 2.

Diagnostic Reasoning

Established Bipolar I Disorder

The patient meets full criteria for Bipolar I Disorder based on:

• Acute manic episode with psychotic features (August 2024): Paranoid delusions, grandiosity, tactile hallucinations, severe insomnia (3-hour increments), uncharacteristic confrontational behavior, and functional impairment requiring three separate psychiatric hospitalizations 3, 2
• Duration criterion met: Symptoms persisted for weeks across multiple admissions
• Exclusion of substance-induced mania: While the patient had prior THC use, the manic episode occurred after cessation of substances
• Prior major depressive episode (early 2023): Responded well to escitalopram, suggesting mood disorder vulnerability

The current presentation represents the depressive phase of bipolar disorder, characterized by guilt, indecisiveness, decreased libido, concentration difficulties, and anhedonia—all occurring in the context of established Bipolar I 4.

Comorbid Generalized Anxiety Disorder

The patient has lifelong baseline anxiety dating to childhood, characterized by:

• Persistent worry across multiple domains (not just mood-related)
• Social inhibition and shyness since childhood
• Family history of anxiety in mother
• Anxiety predating any mood episodes
• Current restlessness, shakiness, and persistent worry

This pattern is consistent with comorbid GAD, which occurs in 50-60% of patients with mood disorders 5. The anxiety represents a separate, chronic condition rather than solely a manifestation of bipolar depression 5.

Key Differential Diagnoses

1. Schizoaffective Disorder, Bipolar Type

Less likely but must be considered given the severity and duration of psychotic symptoms during the manic episode.

Arguments against:

• Psychotic symptoms resolved completely with mood stabilization
• No evidence of psychosis persisting beyond the mood episode
• The patient's psychotic symptoms (paranoia, grandiosity, hallucinations) were temporally limited to the acute manic phase
• Per DSM criteria, schizoaffective requires psychosis for ≥2 weeks in the absence of prominent mood symptoms 3—this patient's psychosis resolved when mania was treated

When to reconsider: If psychotic symptoms re-emerge during euthymic periods or persist despite mood stabilization.

2. Borderline Personality Disorder

Warrants consideration given:

• Interpersonal sensitivity (perceived rejection by family during trip)
• Emotional reactivity to stressors
• Anxiety since childhood

Arguments against:

• No history of self-harm, suicide attempts, or chronic suicidality
• No pattern of unstable relationships or fear of abandonment
• No chronic feelings of emptiness
• The acute episode was clearly manic with psychosis, not emotional dysregulation
• Excellent premorbid functioning (nursing degree, stable employment)
• The manic episode was discrete and episodic, not consistent with chronic personality pathology 6

Critical distinction: BPD with substance use can mimic mania, but this patient had a clear, sustained manic episode with psychosis requiring hospitalization—far exceeding typical BPD emotional dysregulation 6.

3. Substance/Medication-Induced Bipolar Disorder

Must be ruled out given:

• Prior THC use
• Discontinuation of escitalopram before the manic episode

Arguments against:

• Manic episode occurred months after stopping escitalopram (August 2024 vs. late August 2023 discontinuation)
• Patient had stopped THC use before the episode
• The episode's severity, duration, and psychotic features exceed typical SSRI-induced activation
• Per DSM-5, if symptoms persist beyond expected substance effects and require independent treatment, primary bipolar disorder is diagnosed 2

Note: The FDA label for olanzapine acknowledges that suicide risk is inherent in bipolar disorder and schizophrenia, supporting the primary psychiatric diagnosis 7.

4. Major Depressive Disorder with Anxious Distress

Definitively ruled out by the documented manic episode with psychotic features. Once a manic episode occurs, the diagnosis converts from MDD to Bipolar I, regardless of current depressive symptoms 2.

5. Medical/Neurological Causes

Low probability but require exclusion:

• Pituitary cyst with hyperprolactinemia (previously identified, attributed to escitalopram)
• Delirium (ruled out by intact consciousness and orientation)
• Autoimmune encephalitis (would expect more cognitive impairment)
• Thyroid dysfunction (should be checked given mood instability)

The ACR guidelines emphasize excluding medical causes of psychosis, particularly in first episodes 8, 1. However, this patient's presentation is most consistent with primary psychiatric illness.

Current Clinical State: Post-Manic Residual Phase

The patient is experiencing:

• Residual depressive symptoms: Guilt, indecisiveness, decreased libido, anhedonia
• Persistent anxiety: Likely representing both baseline GAD and medication side effects
• Medication-induced sedation: Olanzapine 20 mg causing daytime drowsiness, cognitive clouding, fatigue
• No active psychosis or mania: Appropriate for the recovery phase (6-18 months post-episode) 9

Clinical Pitfalls to Avoid

1. Mistaking residual symptoms for treatment failure: The patient is only months post-manic episode; full recovery takes 6-18 months 9

2. Premature antipsychotic discontinuation: Despite side effects, the patient requires ongoing antipsychotic coverage given recent severe psychotic mania 2, 9, 7

3. Overlooking comorbid GAD: The lifelong anxiety pattern requires separate attention beyond bipolar treatment 5

4. Misattributing all symptoms to medication: While olanzapine causes sedation, the patient also has genuine depressive and anxiety symptoms requiring treatment 7, 4

5. Confusing personality pathology with bipolar disorder: The acute, episodic nature and psychotic features clearly indicate Bipolar I, not BPD 6

Monitoring Priorities

Given olanzapine's metabolic risks, the FDA label mandates:

• Fasting glucose monitoring: At baseline and periodically (hyperglycemia risk) 7
• Lipid panels: Dyslipidemia monitoring
• Weight tracking: Significant weight gain risk
• Suicide risk assessment: Inherent in bipolar disorder 7

The patient's persistent sedation and cognitive clouding warrant consideration of dose reduction or switching to a less sedating antipsychotic (quetiapine, lurasidone, cariprazine), while maintaining mood stabilization with lithium 4.